GSK Sues Moderna Over Patent Claims on COVID-19 and RSV Vaccines

GSK has initiated legal proceedings against Moderna, alleging that the biotech giant infringed on its patented mRNA technology used in Moderna's COVID-19 vaccine, Spikevax, and its RSV vaccine, mResvia. The lawsuits, filed in the U.S. District Court for the District of Delaware, assert that Moderna utilized GSK's proprietary technology without proper licensing, and GSK is seeking damages and licensing fees[1]. The patents at the heart of this dispute originate from innovations by Christian Mandl’s team at Novartis, which GSK acquired in 2015, and are said to be fundamental to Moderna's vaccine formulations[2]. This action is part of GSK's broader strategy to defend its mRNA technology, following similar lawsuits involving other pharmaceutical companies[3].